Alpha 2.0
Login Register
» Authors » Kevin J Petty

Kevin J Petty

Explore the profile of Kevin J Petty including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 390
Followers 0
Related Specialties
Pharmacology
Oncology
Psychiatry
Top 10 Co-Authors
Anup K Majumdar
Keith M Gottesdiener
M Gail Murphy
Anup Majumdar
Michael R Goldberg
Hugh M Davis
Cynthia Gargano
Honghui Zhou
Marvin Constanzer
Howard E Greenberg
Published In
J Clin Pharmacol
Clin Pharmacol Ther
Clin Ther
Cancer Chemother Pharmacol
Clin Drug Investig
Affiliations
Soon will be listed here.
Recent Articles
1.
Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial
Zhuang Y, Lyn S, Lv Y, Xu Z, Bouman-Thio E, Masterson T, et al.
Clin Drug Investig . 2013 Aug; 33(11):795-800. PMID: 23975656
Background And Objectives: Golimumab is an anti-tumor necrosis factor-α human immunoglobulin G1κ monoclonal antibody that is efficacious for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing...
2.
Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state
Te Beek E, Tatosian D, Majumdar A, Selverian D, Klaassen E, Petty K, et al.
J Clin Pharmacol . 2013 Jun; 53(8):846-56. PMID: 23775877
Recent interest in NK1 receptor antagonists has focused on a potential role in the treatment of drug addiction and substance abuse. In the present study, the potential for interactions between...
3.
Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies
Zhu Y, Wang Q, Frederick B, Bouman-Thio E, Marini J, Keen M, et al.
Clin Drug Investig . 2013 Mar; 33(4):291-301. PMID: 23512638
Background And Objective: Ustekinumab, a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody against interleukin-12/23p40, has been reported to be significantly efficacious in treating patients with moderate-to-severe plaque psoriasis. Although the...
4.
Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects
Zhuang Y, Xu Z, de Vries D, Wang Q, Shishido A, Comisar C, et al.
Int J Clin Pharmacol Ther . 2013 Jan; 51(3):187-99. PMID: 23357841
Objective: Sirukumab (CNTO 136) is a human mAb with high affinity and specificity for binding to interleukin-6. This Phase 1 study evaluated the pharmacokinetics, immunogenicity, safety, and tolerability of sirukumab...
5.
Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study
van Hartingsveldt B, Nnane I, Bouman-Thio E, Loza M, Piantone A, Davis H, et al.
Br J Clin Pharmacol . 2012 Oct; 75(5):1289-98. PMID: 23043368
Aims: To assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of CNTO 5825 following single-dose intravenous (i.v.) and subcutaneous (s.c.) administration in healthy and healthy atopic subjects. Methods:...
6.
Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study
Zhuang Y, Xu Z, Frederick B, de Vries D, Ford J, Keen M, et al.
Clin Ther . 2011 Dec; 34(1):77-90. PMID: 22169051
Background: The pharmacokinetics of golimumab, a human monoclonal antibody that inhibits the activity of tumor necrosis factor α, after a single subcutaneous (SC) or intravenous (IV) administration have been previously...
7.
Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway
Judson M, Marchell R, Mascelli M, Piantone A, Barnathan E, Petty K, et al.
J Am Acad Dermatol . 2011 Sep; 66(6):901-10, 910.e1-2. PMID: 21924794
Background: Cutaneous sarcoidosis (CS) skin provides relatively noninvasive access to granulomatous sarcoidosis tissue. Objective: We sought to explore the role of the T-helper (Th)1 and Th17 pathways in sarcoidosis. Methods:...
8.
Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant
Stoch S, Gargano C, Valentine J, Braun M, Murphy M, Fedgchin M, et al.
Cancer Chemother Pharmacol . 2010 Aug; 67(6):1313-21. PMID: 20734049
Purpose: Because glucocorticoids and the neurokinin-1 receptor antagonist aprepitant influence CYP3A4 activity, this study assessed whether aprepitant added to a 5-HT(3) antagonist and glucocorticoid would affect CYP3A4 induction. Methods: In...
9.
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist
Atack J, Maubach K, Wafford K, OConnor D, Rodrigues A, Evans D, et al.
J Pharmacol Exp Ther . 2009 Aug; 331(2):470-84. PMID: 19704033
3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d][1,2,4]triazine (MRK-016) is a pyrazolotriazine with an affinity of between 0.8 and 1.5 nM for the benzodiazepine binding site of native rat brain and recombinant human alpha1-, alpha2-, alpha3-, and...
10.
Effect of aprepitant on the pharmacokinetics of intravenous midazolam
Majumdar A, Yan K, Selverian D, Barlas S, Constanzer M, Dru J, et al.
J Clin Pharmacol . 2007 Apr; 47(6):744-50. PMID: 17463213
Oral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in 12 subjects randomized to intravenous midazolam...